Related Experiment Video
Updated: Dec 26, 2025
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
[Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer]
Yoshinori Kagawa1, Taishi Hata, Atsushi Naito
1Dept. of Surgery, Kansai Rosai Hospital.
Background:
Aflibercept beta and FOLFIRI combination therapy were approved for metastatic colorectal cancer as secondline treatment in 2017. Aflibercept beta is a recombinant fusion protein that traps vascular endothelial growth factor(VEGF)- A, VEGF-B, and placental growth factor(PlGF).
Methods:
We retrospectively evaluated the efficacy and safety of aflibercept beta and FOLFIRI in metastatic colorectal cancer patients(pts)between June 2017 and April 2018 at our institution. Afliber- cept beta(4mg/kg)was administered with FOLFIRI every 2weeks.
Results:
Twenty pts received aflibercept beta and FOLFIRI. There were 11 males and 9 females, with a median age of 69.5(53-81)years. Performance status(PS)was 0 in 12 pts and 1 in the remaining 8 pts. Aflibercept beta and FOLFIRI were prescribed as second-line treatment in 8 pts and the others in 12 pts. The median number of aflibercept beta and FOLFIRI cycles was 5(1-11)cycles. Progression -free survival and overall survival have not yet been estimated. In terms of adverse events, serious adverse events of Grade 3 or higher, including Grade 5 neutropenia, were seen among all pts.
Conclusions:
Aflibercept beta and FOLFIRI demonstrated acceptable toxicity in heavily pretreated metastatic colorectal cancer patients.
Insights
Aflibercept beta and FOLFIRI combination therapy showed acceptable toxicity in metastatic colorectal cancer patients. Further evaluation of progression-free and overall survival is pending.
Area of Science:
- Oncology
- Medical Oncology
- Pharmacology
Background:
- Aflibercept beta, a fusion protein targeting VEGF-A, VEGF-B, and PlGF, combined with FOLFIRI, is approved for metastatic colorectal cancer (mCRC) second-line treatment.
- This combination therapy was approved in 2017.
Purpose of the Study:
- To retrospectively evaluate the efficacy and safety of aflibercept beta plus FOLFIRI in mCRC patients.
- To assess the toxicity profile of this combination in a real-world clinical setting.
Main Methods:
- Retrospective evaluation of 20 metastatic colorectal cancer patients treated between June 2017 and April 2018.
- Aflibercept beta (4mg/kg) was administered with FOLFIRI every two weeks.
Main Results:
- Twenty patients (11 male, 9 female, median age 69.5) received the combination therapy.
- The median number of treatment cycles was 5 (range 1-11).
- All patients experienced Grade 3 or higher adverse events, including Grade 5 neutropenia.
Conclusions:
- Aflibercept beta and FOLFIRI demonstrated acceptable toxicity in heavily pretreated metastatic colorectal cancer patients.
- Further studies are needed to estimate progression-free and overall survival.
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Drugs for Treatment of Ulcerative Colitis in IBD